Month: May 2024

BURLINGTON, Mass., May 01, 2024 (GLOBE NEWSWIRE) — Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today reported business updates and financial results for the first quarter of 2024 ending March 31, 2024. Roluperidone NDA Update On February 27, 2024, the Company announced that the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) to its New Drug Application (NDA) for roluperidone (f/k/a MIN-101) for the treatment of negative symptoms in patients with schizophrenia. The Company is in discussions with the FDA regarding the issues and clinical deficiencies raised in the CRL. Phase 1b Clinical Trial (MIN-101C18) In the first quarter of 2024, the Company completed a clinical trial...

Revenue up 20% year-over-year on strong demand Company beat Q1 guidance across key metrics and raises full year guidance based on strong revenue MIAMI, May 01, 2024 (GLOBE NEWSWIRE) — Norwegian Cruise Line Holdings Ltd. (NYSE: NCLH) (together with NCL Corporation Ltd., (“NCLC”), “Norwegian Cruise Line Holdings”, “Norwegian”, “NCLH” or the “Company”) today reported financial results for the first quarter ended March 31, 2024 and provided guidance for the second quarter and full year 2024. First Quarter 2024 Highlights:Generated total revenue of $2.2 billion, a 20% increase compared to the same period in 2023 on 8% capacity growth, with GAAP net income of $17.4 million, or EPS of $0.04. Adjusted EBITDA nearly doubled over the prior year to $464.0 million, above guidance of $450 million. Achieved Adjusted EPS of $0.16, exceeding...

Reports first quarter revenue of $151 million Increased new modalities revenue by 16% year-over-year Increased Filtration (non-COVID) revenue by 12% year-over-year Achieved a nine-month book-to-bill ratio of 1.03WALTHAM, Mass., May 01, 2024 (GLOBE NEWSWIRE) — Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its first quarter (Q1) of 2024, covering the three-month period ended March 31, 2024. The company also reiterated its financial guidance for the full year 2024. Tony J. Hunt, Chief Executive Officer of Repligen said, “We delivered a solid first quarter, with revenue of $151 million and are on track to achieving our first half sales target of $300 to $310 million. For the quarter, our book-to-bill ratio was 0.99 and over the past...

• Consolidated revenues were $704 million, up 8.0%, and up 6.9% on an organic constant currency (OCC) basis for the first quarter of 2024. • Income from continuing operations was $219 million, up 12.9% for the first quarter of 2024. Adjusted EBITDA, a non-GAAP measure, was $380 million, up 11.8%, and up 10.6% on an OCC basis. • Diluted GAAP earnings per share from continuing operations (diluted EPS) were $1.52 for the first quarter of 2024, up 19.7%. Diluted adjusted earnings per share (diluted adjusted EPS), a non-GAAP measure, were $1.63, up 26.4%. • Net cash provided by operating activities was $372 million, up 1.9% and free cash flow, a non-GAAP measure, was $317 million, up 4.2% for the first quarter of 2024. • We paid a cash dividend of 39 cents per share on March 29, 2024, and repurchased $200 million of our common shares during...

First quarter consolidated earnings per diluted share of $0.91, in line with expectations Confirms consolidated earnings guidance of $2.36 to $2.56 per diluted shareSPOKANE, Wash., May 01, 2024 (GLOBE NEWSWIRE) — Avista Corp. (NYSE: AVA) today announced financial results for the first quarter of 2024. Net income and earnings per diluted share for the first quarter of 2024 compared to the first quarter of 2023 are presented in the table below (dollars in thousands, except per-share data):    2024     2023  Net Income (Loss) by Business Segment:            Avista Utilities   $ 67,508     $ 51,627  AEL&P     3,911       4,042  Other     76       (824 )Total net income   $ 71,495     $ 54,845  Earnings (Loss) per Diluted Share by Business Segment:            Avista Utilities   $ 0.86     $ 0.69  AEL&P     0.05       0.05  Other     —       (0.01 )Total...

– Achieved $14.1 Million in Net Revenue from Sales of COSELA® (trilaciclib) for First Quarter 2024 – – Reaffirmed 2024 Net COSELA Revenue Guidance of $60 to $70 Million – – Announced That Updated Efficacy Results from Phase 2 Trial of Trilaciclib in Combination with a TROP2 Antibody-Drug Conjugate (ADC) Will Be Presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting – – Announced That Final Analysis of Phase 3 PRESERVE 2 Trial Evaluating Overall Survival in 1L Metastatic Triple Negative Breast Cancer (mTNBC) Is Expected to Occur in Late Second Quarter of 2024 – – Cash Runway Expected to Extend into the Third Quarter of 2025 – – Management to Host Webcast and Conference Call today at 8:30 AM ET – RESEARCH TRIANGLE PARK, N.C., May 01, 2024...

Q1 2024 Financial HighlightsRecord revenue of $1.5 billion increases 31% year-over-year Record first quarter organic revenue growth of 29%, including four consecutive quarters with organic growth above 20% Net loss of $107 million due to a $214 million pre-tax charge related to a partial repurchase of 2025 convertible notes above par due to stock price appreciation Adjusted EBITDA increases by 56% to $141 million Strong book-to-bill ratio of 1.4x on record contract awards with 51% growth Record total backlog increases 8% to $9.0 billion Increasing fiscal year 2024 guidance ranges for all financial metricsCHANTILLY, Va., May 01, 2024 (GLOBE NEWSWIRE) — Parsons Corporation (NYSE: PSN) today announced financial results for the first quarter ended March 31, 2024. CEO Commentary “Our momentum continues with a strong start to 2024...